20:15 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that a cyclophilin D (CYPD) inhibitor from its NVP025 program led to a greater survival rate in a mouse model of lethal mitochondrial myopathy compared with...
22:35 , Dec 1, 2016 |  BC Innovations  |  Product R&D

De-stressing about NASH

With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders. The move...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV); HIV/AIDS; coronavirus; viral infection Cell culture and in vitro studies identified phenylpyrrolidine-based inhibitors of CYPA, CYPB and CYPD that could help treat HCV, HIV/AIDS, coronavirus and other viral infections. In silico...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclophilin D (CYPD)

Gastrointestinal INDICATION: Pancreatitis In vitro, cell culture and patient sample studies identified four urea-based CYPD inhibitors that could help treat acute pancreatitis. Chemical synthesis and in vitro testing of pyrrolidine urea analogs yielded three compounds that...
08:00 , Feb 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Mitochondrial permeability transition pore (mPTP); cyclophilin D (CYPD) In vitro...
07:00 , Oct 2, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology ...